Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claus Garbe

Showing results (391-400 of 501) with videos related to

Pageof 51
Sort By:
Future Oncology (London, England)|June 13, 2023
COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAFReinhard Dummer, Keith T Flaherty, Caroline Robert, et al.
European Journal of Cancer (Oxford, England : 1990)|August 23, 2019
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and managementHelen J Gogas, Keith T Flaherty, Reinhard Dummer, et al.
British Journal of Cancer|February 14, 2018
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF<sup>V600</sup> mutation-positive melanomaBrigitte Dréno, Paolo A Ascierto, Victoria Atkinson, et al.
European Journal of Cancer (Oxford, England : 1990)|May 9, 2024
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanomaDirk Schadendorf, Reinhard Dummer, Keith T Flaherty, et al.
Future Oncology (London, England)|January 15, 2025
A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanomaDirk Schadendorf, Reinhard Dummer, Keith T Flaherty, et al.
Ebiomedicine|June 9, 2023
Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastasesEftychia Chatziioannou, Jana Roßner, Thazin New Aung, et al.
Pediatric Blood & Cancer|January 20, 2018
Pediatric patients with cutaneous melanoma: A European studyInes B Brecht, Angela De Paoli, Gianni Bisogno, et al.
Pigment Cell & Melanoma Research|September 30, 2010
Genetic and morphologic features for melanoma classificationSigrid M C Broekaert, Ritu Roy, Ichiro Okamoto, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 14, 2018
Quality assurance in melanoma care: The EU-MELACARE studyAntonio Sommariva, Ana-Maria Forsea, Domenic Agius, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2020
Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma CohortsClaus Garbe, Ulrike Keim, Stefan Suciu, et al.
Pageof 51

Showing results (391-400 of 501) with videos related to

Sort By:
Pageof 51
Future Oncology (London, England)|June 13, 2023
COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAFReinhard Dummer, Keith T Flaherty, Caroline Robert, et al.
European Journal of Cancer (Oxford, England : 1990)|August 23, 2019
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and managementHelen J Gogas, Keith T Flaherty, Reinhard Dummer, et al.
British Journal of Cancer|February 14, 2018
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF<sup>V600</sup> mutation-positive melanomaBrigitte Dréno, Paolo A Ascierto, Victoria Atkinson, et al.
European Journal of Cancer (Oxford, England : 1990)|May 9, 2024
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanomaDirk Schadendorf, Reinhard Dummer, Keith T Flaherty, et al.
Future Oncology (London, England)|January 15, 2025
A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanomaDirk Schadendorf, Reinhard Dummer, Keith T Flaherty, et al.
Ebiomedicine|June 9, 2023
Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastasesEftychia Chatziioannou, Jana Roßner, Thazin New Aung, et al.
Pediatric Blood & Cancer|January 20, 2018
Pediatric patients with cutaneous melanoma: A European studyInes B Brecht, Angela De Paoli, Gianni Bisogno, et al.
Pigment Cell & Melanoma Research|September 30, 2010
Genetic and morphologic features for melanoma classificationSigrid M C Broekaert, Ritu Roy, Ichiro Okamoto, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 14, 2018
Quality assurance in melanoma care: The EU-MELACARE studyAntonio Sommariva, Ana-Maria Forsea, Domenic Agius, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2020
Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma CohortsClaus Garbe, Ulrike Keim, Stefan Suciu, et al.
Pageof 51